Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Mildred A Iro; Matthew D Snape; Merryn Voysey; Sena Jawad; Adam Finn; Paul T Heath; Gianni Bona; Susanna Esposito; Javier Diez-Domingo; Roman Prymula; Adefowope Odueyungbo; Daniela Toneatto; Peter Dull; Andrew J Pollard; European Men B Vaccine Study Group

doi:10.1016/j.vaccine.2017.04.081

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Mildred A Iro
, Matthew D Snape
, Merryn Voysey
, Sena Jawad
, Adam Finn
, Paul T Heath
, Gianni Bona
, Susanna Esposito
, Javier Diez-Domingo
, Roman Prymula
, Adefowope Odueyungbo
, Daniela Toneatto
, Peter Dull
, Andrew J Pollard
, European Men B Vaccine Study Group

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

388 Downloads (Pure)

Abstract

[no abstract]

Original language	English
Pages (from-to)	3279
Number of pages	1
Journal	Vaccine
Volume	35
Issue number	24
Early online date	5 May 2017
DOIs	https://doi.org/10.1016/j.vaccine.2017.04.081
Publication status	Published - 31 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Published Erratum

Access to Document

10.1016/j.vaccine.2017.04.081

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Elsevier at https://www.sciencedirect.com/science/article/pii/S0264410X17305820 . Please refer to any applicable terms of use of the publisher.
Final published version, 815 KBLicence: CC BY

Handle.net

Persistent link

Fingerprint

Dive into the research topics of 'Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]'. Together they form a unique fingerprint.

1 Article (Academic Journal)

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial
Iro, M. A., Snape, M. D., Voysey, M., Jawad, S., Finn, A., Heath, P. T., Bona, G., Esposito, S., Diez-Domingo, J., Prymula, R., Odueyungbo, A., Toneatto, D., Dull, P. & Pollard, A. J., 5 Jan 2017, In: Vaccine. 35, 2, p. 395-402 8 p.
Research output: Contribution to journal › Article (Academic Journal) › peer-review

Open Access
File
18 Citations (Scopus)

469 Downloads (Pure)

Cite this

Iro, M. A., Snape, M. D., Voysey, M., Jawad, S., Finn, A., Heath, P. T., Bona, G., Esposito, S., Diez-Domingo, J., Prymula, R., Odueyungbo, A., Toneatto, D., Dull, P., Pollard, A. J., & European Men B Vaccine Study Group (2017). Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. Vaccine, 35(24), 3279. https://doi.org/10.1016/j.vaccine.2017.04.081

Iro, Mildred A ; Snape, Matthew D ; Voysey, Merryn et al. / Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. In: Vaccine. 2017 ; Vol. 35, No. 24. pp. 3279.

@article{b31c9c2a1b1a46fb85dbb43cbb21c5a8,

title = "Corrigendum to {"}Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial{"} [Vaccine 35 (2017) 395-402]",

abstract = "[no abstract]",

keywords = "Published Erratum",

author = "Iro, \{Mildred A\} and Snape, \{Matthew D\} and Merryn Voysey and Sena Jawad and Adam Finn and Heath, \{Paul T\} and Gianni Bona and Susanna Esposito and Javier Diez-Domingo and Roman Prymula and Adefowope Odueyungbo and Daniela Toneatto and Peter Dull and Pollard, \{Andrew J\} and \{European Men B Vaccine Study Group\}",

year = "2017",

month = may,

day = "31",

doi = "10.1016/j.vaccine.2017.04.081",

language = "English",

volume = "35",

pages = "3279",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Limited",

number = "24",

}

Iro, MA, Snape, MD, Voysey, M, Jawad, S, Finn, A, Heath, PT, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Dull, P, Pollard, AJ & European Men B Vaccine Study Group 2017, 'Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]', Vaccine, vol. 35, no. 24, pp. 3279. https://doi.org/10.1016/j.vaccine.2017.04.081

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. / Iro, Mildred A; Snape, Matthew D; Voysey, Merryn et al.
In: Vaccine, Vol. 35, No. 24, 31.05.2017, p. 3279.

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

TY - JOUR

T1 - Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

AU - Iro, Mildred A

AU - Snape, Matthew D

AU - Voysey, Merryn

AU - Jawad, Sena

AU - Finn, Adam

AU - Heath, Paul T

AU - Bona, Gianni

AU - Esposito, Susanna

AU - Diez-Domingo, Javier

AU - Prymula, Roman

AU - Odueyungbo, Adefowope

AU - Toneatto, Daniela

AU - Dull, Peter

AU - Pollard, Andrew J

AU - European Men B Vaccine Study Group

PY - 2017/5/31

Y1 - 2017/5/31

N2 - [no abstract]

AB - [no abstract]

KW - Published Erratum

U2 - 10.1016/j.vaccine.2017.04.081

DO - 10.1016/j.vaccine.2017.04.081

M3 - Comment/debate (Academic Journal)

C2 - 28483197

SN - 0264-410X

VL - 35

SP - 3279

JO - Vaccine

JF - Vaccine

IS - 24

ER -

Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT et al. Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. Vaccine. 2017 May 31;35(24):3279. Epub 2017 May 5. doi: 10.1016/j.vaccine.2017.04.081

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Abstract

UN SDGs

Keywords

Access to Document

Handle.net

Fingerprint

Research output

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial

Cite this